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It has recently been suggested that mood disorders can be characterized by glial pathology as indicated by histopathological
postmortem ﬁndings. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders.
This protein might act as a growth and diﬀerentiation factor. It is located in, and may actively be released by, astro- and
oligodendrocytes. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than
bipolar disorder. Successful antidepressive treatment reduces S100B in major depression whereas there is no evidence of treatment
eﬀects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-speciﬁc enolase is unaltered. By
indicating glial alterations without neuronal changes, serum S100B studies conﬁrm speciﬁc glial pathology in mood disorders in
vivo.S100Bcanberegardedasapotentialdiagnosticbiomarkerformooddisordersandasabiomarkerforsuccessfulantidepressive
treatment.
1. The GlialHypothesisof Mood Disorders
Mooddisorders—onceconsidered“goodprognosisdiseases”
—have, in fact, a less favorable outcome than previously
thought [1, 2]. They are often very severe or even life-
threatening illnesses. It has been suggested that impairment
of neuroplasticity and cellular resilience may underlie their
pathophysiology, and that optimum long-term treatment
may only be achieved by the early use of agents with
neurotrophic or neuroprotective eﬀects. It has further been
proposed that mood disorders are characterized by speciﬁc
glial pathology [3]. Histopathological post mortem ﬁndings
[1, 4–6] consistently showed reductions in glial cell density
or glial cell numbers in prefrontal brain regions, such as
the (subgenual) anterior cingulate cortex, the orbitofrontal
cortex, and dorsolateral prefrontal cortex in association
with reduced prefrontal gray matter in patients with mood
disorders [3, 7–9]. Furthermore, alterations were described
histopathologically for astrocytes [10–13] and oligoden-
drocytes [14–16] in these disorders. Speciﬁc reductions in
oligodendrocytes have also been reported for the amygdala
in major depressive disorder (MDD) [14], and microglial
alterations in bipolar disorder (BD), also including manic
episodes [1].
Rajkowska’s hypothesis [3] of glial pathology in mood
disorders has been supported by a recent study that
speciﬁcally ablated astroglial cells in the prefrontal cortex
of adult rats pharmacologically with L-alpha-aminoadipic
acid (L-AAA) [17]. Indeed, rats treated with L-AAA
showed depressive-like behavior in behavioral tests similar2 Cardiovascular Psychiatry and Neurology
to depression models based on chronic unpredictable stress.
Conversely, the neurotoxic ibotenate did not show any eﬀect.
Remarkably, antidepressive treatment has been shown to
successfully reverse reduction in astroglial density in animal
models of depression [18]. Although density and size of
cortical neurons are reduced in the orbitofrontal and dorso-
lateral prefrontal cortices in mood disorders, these neuronal
reductions seem less pronounced than glial alterations and
are detected only when speciﬁc morphological size-types of
neurons are analyzed in individual cortical layers [1, 6].
2. The GlialMarker ProteinS100B in
Mood Disorders
Previous studies have shown that S100B, which is found
in astro- and oligodendroglia, but not in microglia in
the human brain [19], is altered in both serum [20, 21]
and cerebrospinal ﬂuid in mood disorders. Cerebrospinal
ﬂuid changes have been shown for drug-free depressive
patientscomparedwitheuthymicpatients[22]andinanimal
models of mania [23]. Interestingly, the levels of the glial
marker protein S100B are speciﬁcally altered in the lateral
prefrontal and parietal cortices in BD [24]. Roche et al. [25]
demonstrated that S100B is a susceptibility gene for BD with
psychosis. Although Yang et al. [26, 27] did not ﬁnd an
association between S100B gene polymorphisms and MDD
in a Chinese population, they revealed an inﬂuence on age of
onset and subgroups (ﬁrst-episode versus recurrent episode
depression) of MDD.
S100 proteins areafamilyofacidic proteins thatcanbind
calcium and, thus, inﬂuence various cellular responses along
the calcium-signal-transduction pathway [31–34]. S100B
regulates cell shape, energy metabolism, contraction, cell-
to-cell communication, intracellular signal transduction,
cell growth [35], and can be actively released by astro-
and oligodendrocytes [19, 36]. Interestingly, the eﬀects of
extracellular S100B depend on its concentration [33, 37]. In
a nanomolar concentration S100B can act as growth and/or
diﬀerentiation factor for neurons and astrocytes, whereas
in a micromolar concentration it may induce apoptosis.
Moreover, it has been suggested that S100 proteins, such
as S100B, may play a crucial role in the pathogenesis of
depression and its treatment [38–44].
To better evaluate the relevance of S100B in mood
disorders, we recently conducted a systematic, quantita-
tive meta-analysis using MedLine and Current Contents
search engines (search strategy: [S100 OR S-100] AND
[depression OR mania]) [20, 21]. The following inclusion
criteria were applied: diagnosis according to internationally
recognized diagnostic criteria (International Classiﬁcation
of Diseases, ICD-10; Diagnostic and Statistical Manual of
Mental Disorders, DSM-IV [45, 46]), original and peer-
reviewed studies, comparison with age-matched, healthy
controlsubjectsandnooverlapwithcohortsofotherstudies.
Eight studies involving 193 patients suﬀering from mood
disorders and 132 healthy control subjects were entered into
the meta-analysis. Of the patients, 86 suﬀered from a major



































Figure 1: Eﬀect sizes according to Cohen [28] of S100B serum
concentrationinschizophrenia,andmooddisordersasidentiﬁedby
a systematic meta-analysis [21]. Median is shown for schizophrenia
(solid line), major depressive disorder (MDD, dashed line) and
bipolar disorder (BD, dashed & dotted line).
euthymicatthetimeofinvestigation.Toadjustforsystematic
measurement eﬀects, the eﬀect size of each study (d)w a s
calculated according to Cohen [28] as the diﬀerence of the
means of the patient (mp) and control group (mc)d i v i d e d
by the standard deviation of the control group (SDc). This
measure represents normalized elevations of S100B in the
patient groups. Eﬀect sizes of the studies are shown in
Figure 1.C o h e n[ 28]d e ﬁ n e dv a l u e so f≥ 0.8a sl a r g e ,> 0.5
as medium and > 0.2 as small. The mean eﬀect size reached
high values for all episodes of mood disorders [20], namely
major depressive episode of MDD (2.57 ± 0.70), manic
episode of BD (1.53 ± 0.13) and currently euthymic mood
disorder (2.54±2.48; mean±SD). For major depressive and
manic episodes, values were signiﬁcantly higher than zero,
conﬁrming high serum S100B in acute episodes of mood
disorder (T = 6.4,= 17,df = 2,= 1,P = .024,= .037;
2-tailed Student’s t-test against 0), which was not the case
for currently euthymic mood disorder (T = 1.4,df = 1,
P>. 05).
We set out to compare serum S100B in BD and MDD,
because these types of mood disorder are classiﬁed as
separate nosological entities and because we did not ﬁnd
signiﬁcant diﬀerences between depressive/manic episodes
and remitted mood disorder per se (P>. 05; 2-tailed
unpaired Student’s t-test) [21]. As illustrated in Figure 1,
serum S100B reached high eﬀect sizes in both MDD (3.0 ±
1.03) and BD (1.4 ± 0.44; T = 5.82,= 6.4,df = 3,= 3, P =
.01,= .008; 2-tailed one-sample Student’s t-test against 0).
Eﬀect size was larger in MDD than BD (T = 2.84,df = 6,
P = .029; 2-tailed unpaired Student’s t-test). For mania inCardiovascular Psychiatry and Neurology 3
BD and depression in MDD, only two studies with drug-free
patients were available, each reporting high eﬀect sizes (1.62,
3.3).Sincethemeta-analysiswasconducted,athirdstudyhas
been published with drug-free patients suﬀering from MDD
(eﬀect size 0,96 [47]).
Protein S100B has been detected in numerous other
tissues in the human body besides glial cells, for example,
in adipocytes, melanocytes, chondrocytes, myocardium, and
Schwann cells [33, 35, 48]. Although changes elicited by
adipocytes are at least theoretically possible in mood disor-
ders[49,50],nostudyhasyetreportedchangesinS100Bdue
to the aforementioned extracranial cell types.
Additionally, we compared results of the meta-analysis
for mood disorders with another recent meta-analysis
investigating serum S100B with the same method in 420
patients with schizophrenia [21, 51]. Although eﬀects sizes
also reached large values in schizophrenia (2.02 ± 1.78; T =
4.25,df = 13,P = .001; 2-tailed one-sample Student’s
t-test against 0), there were no signiﬁcant diﬀerences in
comparison with MDD or BD (T =− 1.03,= 0.68,df =
16,= 16,P = .317,= .509; 2-tailed unpaired Student’s
t-test). In sum, results support the hypothesis that S100B is
involved in the pathogenesis of mood disorders, particularly
MDD.
3. Speciﬁcityof Elevations of
Serum S100B inMood Disorders
To validate the histopathologically generated hypothesis that
mood disorders are characterized by speciﬁc glial pathology
[3] in vivo, we recently measured S100B simultaneously with
neuron-speciﬁc enolase (NSE) in the serum of patients with
MDD and healthy age- and gender-matched control subjects
[20]. NSE is located mainly in the cytoplasm of nerve cells
and is not actively secreted [52, 53]. Hence, it has been
regarded as a marker for neuronal injury or brain damage.
If mood disorders are ultimately glial disorders as suggested
by Rajkowska [3], one would expect elevated serum levels of
S100B paralleled by unaltered neuronal marker protein NSE.
Figure 2 illustrates serum concentration of S100B and
NSE in 10 control subjects, and in 10 patients with MDD
at admission and discharge. As hypothesized, S100B con-
centrations were higher in depressive patients at admission
and discharge compared to control subjects. NSE was not
statistically diﬀerent between patients (at admission or
discharge) and control subjects. Moreover, antidepressive
treatment had no signiﬁcant eﬀect on NSE serum levels.
Three other studies have reported ﬁndings on serum NSE
in major depression, but the choice of the according study
sampleswascharacterizedbyconsiderablelimitations.Greﬀe
et al. [54] investigated serum NSE in 6 subjects with
refractorymajordepressionincomparisonto274psychiatric
control patients that were not characterized in more detail.
Similar to our study, they found no diﬀerence between
groups. Another study [55]i n v e s t i g a t e dt r e a t m e n te ﬀects
of clinically successful electroconvulsive therapy on serum
NSE in 7 patients suﬀering from MDD. They did not ﬁnd










































Figure 2: Serum concentrations of S100B and neuron-speciﬁc
enolase (NSE) in patients with major depression immediately
after admission and at discharge, compared with healthy age- and
gender-matched control subjects [20]. P-values are reported for 2-
tailed unpaired Student’s t-test. Mean±SEM.
values were in the normal range across all measurements
without showing control data. A comparable result was
reported by Agelink et al. [56] although they did not
distinguish between their patients with therapy-resistant
major depression and subjects with schizodepressive psy-
chosis. These data suggest that in MDD S100B is elevated
while NSE remains unaltered, providing substantial support
for Rajkowska’s glial hypothesis for mood disorders [3].
However, only one study [57] has investigated NSE in mania
so far, showing decreased values in 30 unmedicated and 15
patients undergoing lithium treatment in comparison with
30 healthy control subjects. These results make it diﬃcult
to generalize speciﬁc glial pathology in MDD to all mood
disorders and have not yet been replicated.
Increased serum levels of S100B may indicate glial
alterations in mood disorders either due to brain damage
[58] or due to functional secretion of S100B by astrocytes
and/or oligodendrocytes [19, 36]. Mathematical models
suggest that levels of serum S100B exceeding approximately
350ng/l indicate brain damage [59]. Mean serum levels
of S100B as reported in our and other studies of mood
disorders do not reach this threshold [20]. Likewise, our
data together with earlier studies exclude possible neuronal4 Cardiovascular Psychiatry and Neurology
damage in MDD and mania as indicated by normal or
even decreased serum NSE values [54, 55, 57]. One might
therefore conclude that brain damage is not the primary
cause of elevated S100B in mood disorders. Some authors
regard serum S100B as a valid marker of blood-brain barrier
integrity[59–63]andastrocytesmightinﬂuenceblood-brain
barrier function [64–66]. Others argue that S100B might
penetrate the blood-brain barrier easily, but this has not
y e tb e e np r o v e ne x p e r i m e n t a l l y[ 67, 68]. Accordingly, it
remains to be clariﬁed whether elevated serum S100B could
indicate an impairment in the blood-brain barrier, as has
been described for depression [69, 70].
4. Treatment Effects on Serum S100B
It has recently been suggested that a loss of neuroplasticity
and cellular resilience may underlie the pathophysiology
of mood disorders and that optimum long-term treatment
can only be achieved by early neurotrophic and/or neu-
roprotective intervention [1, 2]. It is well-established that
extracellular S100B can act as growth and/or diﬀerentiation
factor for neurons and astrocytes via various intracellular
signalcascades[1,33,71–73].Antidepressivedrugsinﬂuence
the secretion of S100B by astrocytes via the serotonergic
system [11, 35, 43, 44, 74–76]. S100B may even induce
neurogenesis[77],whichisrequiredforthebehavioraleﬀects
of antidepressants [78]. It has also been suggested that S100
proteins may play an essential role in the pathogenesis of
depression and its treatment [40, 42], and that S100B-related
mechanisms could be explored as potential targets for novel
antidepressive therapeutics [38, 39]. Interestingly, levels of
serum S100B might predict the response to antidepressive
treatment in MDD [79].
To validate the impact of S100B as a marker for phar-
macological treatment eﬀects, we subsequently conducted
a third systematic, quantitative meta-analysis (see above
for search strategy and inclusion criteria) [20]. This meta-
analysis identiﬁed three studies involving 46 patients with
major depression and one study including 11 patients
with mania. A ﬁfth study examining changes in serum
S100B immediately (1 and 3 hours) after electroconvulsive
treatment did not include a control group [80]a n db e c a u s e
injury mechanisms following electroconvulsive treatment
could represent a potential confounding factor, we did not
include this study inthe meta-analysis.A sixthstudy [56]did
not diﬀerentiate between therapy-resistant major depression
andschizodepressivepsychosiswhenreportingtheirﬁndings
during electroconvulsive therapy, and was, accordingly, also
excluded. The treatment eﬀect size (d) for S100B and the
severity of clinical symptoms was calculated for each study
according to Cohen [28] as the diﬀerence of the means of
the patient group at admission (mad) and discharge (mdis)
divided by the standard deviation at admission (SDad). Such
treatment eﬀect size reveals a measure for relative changes
from baseline.
The mean treatment eﬀect size derived from the three
available studies could be calculated for serum S100B in
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Figure 3: Eﬀect sizes according to Cohen [28] for clinical (HAMD
scores) and serological (serum S100B) treatment eﬀects in major
depression [20]. Eﬀect sizes were calculated as changes between
admission and discharge relative to standard deviation at admission
forthethreeavailablestudies[20,29,30].Severityofdepressionwas
measured with the Hamilton Depression Rating Scale (HAMD).
changes on the HAMD scale (3.47 ± 1.80), with a lower
impact on serum S100B (0.43 ± 0.44; T = 3.3,= 1.7,df =
2,P = .04,= .12; 1-tailed Student’s t-test against 0). As illus-
trated in Figure 3,e ﬀect sizes for clinical improvement dur-
ing treatment (Hamilton Depression Rating Scale, HAMD)
and respective changes of the serological marker S100B were
signiﬁcantly correlated with each other if the relationship
for the three relevant studies involving major depression was
examined (r = 1.0,N = 3,P<. 001; correlation according
to Spearman, 2-tailed p). This signiﬁcant positive correlation
between clinical treatment eﬀects (HAMD) and serological
treatment eﬀects (S100B) indicates that serum S100B may be
a reliable marker for treatment eﬀects in major depression if
clinical improvement is suﬃcient. For mania only one study
examined changes of S100B during treatment, but without
detecting any signiﬁcant eﬀects [29].
However, one has to keep in mind the limitations of the
meta-analysis for these treatment studies. All of the clinical
studies on serum S100B in mood disorders involved several
antidepressive/antimanic drugs or combinations with other
psychotropic agents such as neuroleptics when psychotic
symptoms were present [20]. Likewise, treatment studies to
date have experienced signiﬁcant limitations of sample size.
Hence, future well-powered clinical studies are necessary
to overcome this limitation. Furthermore, in vitro (cell
culture) studies examining eﬀects of diﬀerent antidepressive
treatment strategies on S100B with regard to the speciﬁc
signaling pathways of the neurotransmitter system mainly
targeted by the antidepressant would be of high interest.
5. Evidence from Studies with Serum Markers
for the Glial Hypothesis of Mood Disorders
To summarize ﬁndings from the literature supporting the
hypothesis of glial pathology in mood disorders [3], we listCardiovascular Psychiatry and Neurology 5
the following key ﬁndings:
(i) Serum concentrations of the glial marker protein
S100B are elevated in patients with mood disorder,
major depression and mania, when compared with
healthy control subjects.
(ii) Serum S100B is higher in major depressive disorder
than bipolar disorder.
(iii) Successful antidepressive treatment reduces S100B in
major depression. While only one study investigated
treatment eﬀects in mania, such an eﬀect could not
be found.
(iv) The neuronal marker protein NSE is unaltered in
major depression and its treatment. NSE is not
increased in mania; the only study in the literature
reported mildly reduced serum levels.
(v) Data support the hypothesis that elevated serum
S100B is related to active secretion by astrocytes
and/or oligodendrocytes in acute episodes of mood
disorders, particularly major depressive disorder, and
that this secretion might decline with successful
antidepressive treatment.
In conclusion, these ﬁndings strongly support the con-
cept of serum S100B as a reliable and sensitive diagnostic
biomarker for mood disorders and the clinical response to
antidepressive treatment in unipolar major depressive disor-
der. Evidence of glial changes without neuronal alterations
from in vivo studies is consistent with the histopathologically
generated hypothesis that mood disorders are characterized
by speciﬁc glial pathology.
References
[ 1 ]H .K .M a n j i ,G .J .M o o r e ,G .R a j k o w s k a ,a n dG .C h e n ,
“Neuroplasticity and cellular resilience in mood disorders,”
Molecular Psychiatry, vol. 5, no. 6, pp. 578–593, 2000.
[2] C. Pittenger and R. S. Duman, “Stress, depression, and
neuroplasticity: a convergence of mechanisms,” Neuropsy-
chopharmacology, vol. 33, no. 1, pp. 88–109, 2008.
[3] G. Rajkowska, “Dysfunction in neural circuits involved in the
pathophysiology of mood disorders: postmortem studies in
mood disorders indicate altered numbers of neurons and glial
cells,” Biological Psychiatry, vol. 48, no. 8, pp. 766–777, 2000.
[4] D. R. Cotter, C. M. Pariante, and I. P. Everall, “Glial cell
abnormalities in major psychiatric disorders: the evidence and
implications,” Brain Research Bulletin, vol. 55, no. 5, pp. 585–
595, 2001.
[5] P. J. Harrison, “The neuropathology of primary mood disor-
der,” Brain, vol. 125, no. 7, pp. 1428–1449, 2002.
[6] G. Rajkowska and J. J. Miguel-Hidalgo, “Gliogenesis and glial
pathology in depression,” CNS and Neurological Disorders—
Drug Targets, vol. 6, no. 3, pp. 219–233, 2007.
[7] D. Cotter, D. Mackay, S. Landau, R. Kerwin, and I. Everall,
“Reduced glial cell density and neuronal size in the anterior
cingulate cortex in major depressive disorder,” Archives of
General Psychiatry, vol. 58, no. 6, pp. 545–553, 2001.
[8] D. ¨ Ong¨ ur,W.C.Drevets,andJ.L.Price,“Glialreductioninthe
subgenual prefrontal cortex in mood disorders,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 95, no. 22, pp. 13290–13295, 1998.
[9] G. Rajkowska, J. J. Miguel-Hidalgo, J. Wei, et al., “Morphome-
tric evidence for neuronal and glial prefrontal cell pathology
in major depression,” Biological Psychiatry,v o l .4 5 ,n o .9 ,p p .
1085–1098, 1999.
[10] N. L. Johnston-Wilson, C. D. Sims, J. P. Hofmann, et al.,
“Disease-speciﬁc alterations in frontal cortex brain proteins
in schizophrenia, bipolar disorder, and major depresssive
disorder,” Molecular Psychiatry, vol. 5, no. 2, pp. 142–149,
2000.
[11] J. J. Miguel-Hidalgo, C. Baucom, G. Dilley, et al., “Glial
ﬁbrillary acidic protein immunoreactivity in the prefrontal
cortex distinguishes younger from older adults in major
depressive disorder,” Biological Psychiatry,v o l .4 8 ,n o .8 ,p p .
861–873, 2000.
[12] X. Si, J. J. Miguel-Hidalgo, G. O’Dwyer, C. A. Stockmeier,
and G. Rajkowska, “Age-dependent reductions in the level of
glial ﬁbrillary acidic protein in the prefrontal cortex in major
depression,” Neuropsychopharmacology, vol. 29, no. 11, pp.
2088–2096, 2004.
[13] M. J. Webster, N. Johnston-Wislon, K. Nagata, and R. H.
Yolken, “Alterations in the expression of phosphorylated glial
ﬁbrillary acidic proteins in the frontal cortex of individ-
uals with schizophrenia, bipolar disorder, and depression,”
Schizophrenia Research, vol. 41, p. 106, 2000.
[14] M. Hamidi, W. C. Drevets, and J. L. Price, “Glial reduction in
amygdala in major depressive disorder is due to oligodendro-
cytes,” Biological Psychiatry, vol. 55, no. 6, pp. 563–569, 2004.
[15] N. A. Uranova, V. M. Vostrikov, D. D. Orlovskaya, and
V. I. Rachmanova, “Oligodendroglial density in the pre-
frontal cortex in schizophrenia and mood disorders: a study
from the Stanley Neuropathology Consortium,” Schizophrenia
Research, vol. 67, no. 2-3, pp. 269–275, 2004.
[16] V.M.Vostrikov,N.A.Uranova,andD.D.Orlovskaya,“Deﬁcit
of perineuronal oligodendrocytes in the prefrontal cortex in
schizophrenia and mood disorders,” Schizophrenia Research,
vol. 94, no. 1–3, pp. 273–280, 2007.
[17] M.BanasrandR.S.Duman,“Gliallossintheprefrontalcortex
is suﬃcient to induce depressive-like behaviors,” Biological
Psychiatry, vol. 64, no. 10, pp. 863–870, 2008.
[18] B. Cz´ e h ,M .S i m o n ,B .S c h m e l t i n g ,C .H i e m k e ,a n dE .F u c h s ,
“Astroglial plasticity inthe hippocampus isaﬀected by chronic
psychosocial stress and concomitant ﬂuoxetine treatment,”
Neuropsychopharmacology,vol.31,no.8,pp.1616–1626,2006.
[19] J. Steiner, H. G. Bernstein, H. Bielau, et al., “Evidence for a
wide extra-astrocytic distribution of S100B in human brain,”
BMC Neuroscience, vol. 8, article 2, 2007.
[20] M. L. Schroeter, H. Abdul-Khaliq, M. Krebs, A. Diefenbacher,
and I. E. Blasig, “Serum markers support disease-speciﬁc glial
pathology in major depression,” Journal of Aﬀective Disorders,
vol. 111, no. 2-3, pp. 271–280, 2008.
[21] M. L. Schroeter and J. Steiner, “Elevated serum levels of the
glial marker protein S100B are not speciﬁc for schizophrenia
or mood disorders,” Molecular Psychiatry,v o l .1 4 ,n o .3 ,p p .
235–237, 2009.
[22] H. J. Grabe, N. Ahrens, H. J. Rose, C. Kessler, and H. J. Frey-
berger, “Neurotrophic factor S100beta in major depression,”
Neuropsychobiology, vol. 44, no. 2, pp. 88–90, 2001.
[23] R.M ac hado-V ieira,A.P .Sc hmidt,T .T .´ Avila,etal.,“Increased
cerebrospinal ﬂuid levels of S100B protein in rat model of
mania induced by ouabain,” Life Sciences, vol. 76, no. 7, pp.
805–811, 2004.
[24] B. Dean, L. Gray, and E. Scarr, “Regionally speciﬁc changes
in levels of cortical S100β in bipolar 1 disorder but not6 Cardiovascular Psychiatry and Neurology
schizophrenia,” Australian and New Zealand Journal of Psychi-
atry, vol. 40, no. 3, pp. 217–224, 2006.
[25] S. Roche, F. Cassidy, C. Zhao, et al., “Candidate gene analysis
of21q22:supportforS100Basasusceptibilitygeneforbipolar
aﬀective disorder with psychosis,” American Journal of Medical
Genetics Part B, vol. 144, no. 8, pp. 1094–1096, 2007.
[26] K. Yang, Y. Q. Hu, G. R. Xie, F. Q. Mao, and L. Y. Su, “No
association of the rs9722 C > T in the S100B gene and
susceptibility to major depression in a Chinese population,”
Genetic Testing, vol. 12, no. 4, pp. 487–489, 2008.
[27] K. Yang, G.-R. Xie, Y.-Q. Hu, F.-Q. Mao, and L.-Y. Su,
“Association study of astrocyte-derived protein S100B gene
polymorphisms with major depressive disorder in Chinese
people,”CanadianJournalofPsychiatry,vol.54,no.5,pp.312–
319, 2009.
[28] J. Cohen, Statistical Power Analysis for the Behavioral Sciences,
Lawrence Earlbaum Associates, Hillsdale, NJ, USA, 2nd
edition, 1988.
[29] M. L. Schroeter, H. Abdul-Khaliq, A. Diefenbacher, and I. E.
Blasig, “S100B is increased in mood disorders and may be
reduced by antidepressive treatment,” NeuroReport, vol. 13,
no. 13, pp. 1675–1678, 2002.
[ 3 0 ]G .H e t z e l ,O .M o e l l e r ,S .E v e r s ,e ta l . ,“ T h ea s t r o g l i a lp r o t e i n
S100B and visually evoked event-related potentials before and
after antidepressant treatment,” Psychopharmacology, vol. 178,
no. 2-3, pp. 161–166, 2005.
[31] E. Raponi, F. Agenes, C. Delphin, et al., “S100B expression
deﬁnes a state in which GFAP-expressing cells lose their neural
stem cell potential and acquire a more mature developmental
stage,” GLIA, vol. 55, no. 2, pp. 165–177, 2007.
[32] L. Santamaria-Kisiel, A. C. Rintala-Dempsey, and G. S. Shaw,
“Calcium-dependent and -independent interactions of the
S100 protein family,” Biochemical Journal, vol. 396, no. 2, pp.
201–214, 2006.
[33] B. W. Sch¨ afer and C. W. Heizmann, “The S100 family of
EF-hand calcium-binding proteins: functions and pathology,”
Trends in Biochemical Sciences, vol. 21, no. 4, pp. 134–140,
1996.
[34] M. L. Schroeter, H. Abdul-Khaliq, S. Fr¨ uhauf, et al., “Serum
S100B is increased during early treatment with antipsychotics
and in deﬁcit schizophrenia,” Schizophrenia Research, vol. 62,
no. 3, pp. 231–236, 2003.
[35] D. B. Zimmer, E. H. Cornwall, A. Landar, and W. Song, “The
S100 protein family: history, function, and expression,” Brain
Research Bulletin, vol. 37, no. 4, pp. 417–429, 1995.
[36] S. S. Pinto, C. Gottfried, A. Mendez, et al., “Immunocontent
and secretion of S100B in astrocyte cultures from diﬀerent
brain regions in relation to morphology,” FEBS Letters, vol.
486, no. 3, pp. 203–207, 2000.
[37] K. R. L. Schmitt, C. Kern, P. E. Lange, F. Berger, H.
Abdul-Khaliq, and S. Hendrix, “S100B modulates IL-6
release and cytotoxicity from hypothermic brain cells and
inhibits hypothermia-induced axonal outgrowth,” Neuro-
science Research, vol. 59, no. 1, pp. 68–73, 2007.
[38] E. C. Azmitia and P. M. Whitaker-Azmitia, “Anatomy, cell
biology and plasticity of the serotonergic system: neu-
ropsychopharmacological implications for the action of psy-
chotrophic drugs,” in Psychopharmacology: The Fourth Gener-
ation of Progress, D. Kupfer and F. Bloom, Eds., pp. 443–450,
Raven Press, New York, NY, USA, 1995.
[39] H. Manev, T. Uz, and R. Manev, “Glia as a putative target for
antidepressant treatments,” Journal of Aﬀective Disorders, vol.
75, no. 1, pp. 59–64, 2003.
[40] H. Manev and R. Manev, “Nomen est Omen: do antide-
pressants increase p11 or S100A10?” Journal of Biomedical
Discovery and Collaboration, vol. 1, no. 1, article 5, 2006.
[41] H. Manev and R. Manev, “Olanzapine and S100 proteins,”
Neuropsychopharmacology, vol. 31, no. 11, p. 2567, 2006.
[42] P. Svenningsson, K. Chergui, I. Rachleﬀ, et al., “Alterations
in 5-HT1B receptor function by p11 in depression-like states,”
Science, vol. 311, no. 5757, pp. 77–80, 2006.
[43] P. M. Whitaker-Azmitia, R. Murphy, and E. C. Azmitia,
“Stimualtion of astroglial 5-HT1A receptors releases the sero-
tonergic growth factor, protein S-100, and alters astroglial
morphology,” Brain Research, vol. 528, no. 1, pp. 155–158,
1990.
[44] P. M. Whitaker-Azmitia, C. Clarke, and E. C. Azmitia, “Local-
ization of 5-HT1A receptors to astroglial cells in adult rats:
implications for neuronal-glial interactions and psychoactive
drug mechanism of action,” Synapse, vol. 14, no. 3, pp. 201–
205, 1993.
[45] American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders, American Psychiatric Press,
Washington, DC, USA, 4th edition, 1994.
[46] World Health Organization, The ICD-10 Classiﬁcation of
Mental and Behavioural Disorders: Diagnostic Criteria for
Research (DCR), WHO, Geneva, Switzerland, 1993.
[ 4 7 ]K .Y a n g ,G .R .X i e ,Y .Q .H u ,F .Q .M a o ,a n dL .Y .S u ,“ T h e
eﬀectsofgenderandnumbersofdepressiveepisodesonserum
S100B levels in patients with major depression,” Journal of
Neural Transmission, vol. 115, no. 12, pp. 1687–1694, 2008.
[48] R. Donato, “S100: a multigenic family of calcium-modulated
proteins of the EF-hand type with intracellular and extracellu-
lar functional roles,” International Journal of Biochemistry and
Cell Biology, vol. 33, no. 7, pp. 637–668, 2001.
[49] G. M. Jow, T. T. Yang, and C. L. Chen, “Leptin and cholesterol
levels are low in major depressive disorder, but high in
schizophrenia,” Journal of Aﬀective Disorders,v o l .9 0 ,n o .1 ,p p .
21–27, 2006.
[50] J. Steiner, K. Schiltz, M. Walter, et al., “S100B serum levels are
closely correlated with body mass index: an important caveat
in neuropsychiatric research,” Psychoneuroendocrinology, vol.
35, no. 2, pp. 321–324, 2010.
[51] M. L. Schroeter, H. Abdul-Khaliq, M. Krebs, A. Diefenbacher,
and I. E. Blasig, “Neuron-speciﬁc enolase is unaltered whereas
S100B is elevated in serum of patients with schizophrenia—
original research and meta-analysis,” Psychiatry Research, vol.
167, no. 1-2, pp. 66–72, 2009.
[52] E. V. Potapov, M. Loebe, H. Abdul-Khaliq, et al., “Postopera-
tive course of S-100B protein and neuron-speciﬁc enolase in
patients after implantation of continuous and pulsatile ﬂow
LVADs,” JournalofHeartandLungTransplantation,vol.20,no.
12, pp. 1310–1316, 2001.
[53] J. Steiner, H. Bielau, H. G. Bernstein, B. Bogerts, and M. T.
Wunderlich, “Increased cerebrospinal ﬂuid and serum levels
of S100B in ﬁrst-onset schizophrenia are not related to a
degenerative release of glial ﬁbrillar acidic protein, myelin
basic protein and neurone-speciﬁc enolase from glia or
neurones,” Journal of Neurology, Neurosurgery and Psychiatry,
vol. 77, no. 11, pp. 1284–1287, 2006.
[54] J. Greﬀe, P. Lemoine, C. Lacroix, et al., “Increased serum
levels of neuron-speciﬁc enolase in epileptic patients and
afterelectroconvulsivetherapy—apreliminaryreport,”Clinica
Chimica Acta, vol. 244, no. 2, pp. 199–208, 1996.
[55] J. Berrouschot, K. Rolle, H. J. K¨ uhn, and D. Schneider,
“Serum neuron-speciﬁc enolase levels do not increase afterCardiovascular Psychiatry and Neurology 7
electroconvulsive therapy,” Journal of the Neurological Sciences,
vol. 150, no. 2, pp. 173–176, 1997.
[56] M. W. Agelink, J. Andrich, T. Postert, et al., “Relation
between electroconvulsive therapy, cognitive side eﬀects, neu-
ron speciﬁc enolase, and protein S-100,” J o u r n a lo fN e u r o l o g y
Neurosurgery and Psychiatry, vol. 71, no. 3, pp. 394–396, 2001.
[57] R. Machado-Vieira, A. C. Andreazza, C. I. Viale, et al.,
“Oxidative stress parameters in unmedicated and treated
bipolar subjects during initial manic episode: a possible role
for lithium antioxidant eﬀects,” Neuroscience Letters, vol. 421,
no. 1, pp. 33–36, 2007.
[58] H. Abdul-Khaliq, S. Schubert, G. Stoltenburg-Didinger, et al.,
“Protein S-100β in brain and serum after deep hypothermic
circulatory arrest in rabbits: relationship to perivascular astro-
cytic swelling,” Clinical Chemistry and Laboratory Medicine,
vol. 38, no. 11, pp. 1169–1172, 2000.
[59] N.Marchi,M.Cavaglia,V.Fazio,S.Bhudia,K.Hallene,andD.
Janigro, “Peripheral markers of blood-brain barrier damage,”
Clinica Chimica Acta, vol. 342, no. 1-2, pp. 1–12, 2004.
[60] A. A. Kanner, N. Marchi, V. Fazio, et al., “Serum S100β:a
noninvasive marker of blood-brain barrier function and brain
lesions,” Cancer, vol. 97, no. 11, pp. 2806–2813, 2003.
[61] M. Kapural, L. Krizanac-Bengez, G. Barnett, et al., “Serum S-
100β as a possible marker of blood-brain barrier disruption,”
Brain Research, vol. 940, no. 1-2, pp. 102–104, 2002.
[62] N.Marchi,P.Rasmussen,M.Kapural,etal.,“Peripheralmark-
ers of brain damage and blood-brain barrier dysfunction,”
Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp.
109–121, 2003.
[63] A. Regner, M. Kaufman, G. Friedman, and I. Chemale,
“Increased serum S100β protein concentrations following
severe head injury in humans: a biochemical marker of brain
death?” NeuroReport, vol. 12, no. 4, pp. 691–694, 2001.
[64] K. Kacem, P. Lacombe, J. Seylaz, and G. Bonvento, “Structural
organization of the perivascular astrocyte endfeet and their
relationship with the endothelial glucose transporter: a con-
focal microscopy study,” GLIA, vol. 23, no. 1, pp. 1–10, 1998.
[65] M. L. Schroeter, K. Mertsch, H. Giese, et al., “Astrocytes
enhance radical defence in capillary endothelial cells consti-
tuting the blood-brain barrier,” FEBS Letters, vol. 449, no. 2-3,
pp. 241–244, 1999.
[66] M. L. Schroeter, S. M¨ uller, J. Lindenau, et al., “Astrocytes
induce manganese superoxide dismutase in brain capillary
endothelial cells,” NeuroReport, vol. 12, no. 11, pp. 2513–2517,
2001.
[67] M. Rothermundt, P. Falkai, G. Ponath, et al., “Glial cell
dysfunction in schizophrenia indicated by increased S100B in
the CSF,” Molecular Psychiatry, vol. 9, no. 10, pp. 897–899,
2004.
[68] M. Rothermundt, G. Ponath, and V. Arolt, “S100B in schizo-
phrenic psychosis,” International Review of Neurobiology, vol.
59, pp. 445–470, 2003.
[69] H. Hampel, H. U. K¨ otter, and H. J. M¨ oller, “Blood-
cerebrospinal ﬂuid barrier dysfunction for high molecular
weight proteins in alzheimer disease and major depression:
indication for disease subsets,” Alzheimer Disease and Associ-
ated Disorders, vol. 11, no. 2, pp. 78–87, 1997.
[70] O. C. G. Zachrisson, J. Balldin, R. Ekman, et al., “No evident
neuronal damage after electroconvulsive therapy,” Psychiatry
Research, vol. 96, no. 2, pp. 157–165, 2000.
[71] D. K¨ ogel, M. Peters, H. G. K¨ onig, et al., “S100B potently
activates p65/c-Rel transcriptional complexes in hippocampal
neurons: clinical implications for the role of S100B in
excitotoxicbraininjury,”Neuroscience,vol.127,no.4,pp.913–
920, 2004.
[72] G. Ponath, C. Schettler, F. Kaestner, et al., “Autocrine S100B
eﬀects on astrocytes are mediated via RAGE,” Journal of
Neuroimmunology, vol. 184, no. 1-2, pp. 214–222, 2007.
[73] P. T. Wilder, J. Lin, C. L. Bair, et al., “Recognition of the
tumor suppressor protein p53 and other protein targets by
the calcium-binding protein S100B,” Biochimica et Biophysica
Acta, vol. 1763, no. 11, pp. 1284–1297, 2006.
[74] M. J. Carson, E. A. Thomas, P. E. Danielson, and J. G. Sutcliﬀe,
“The 5-HT1A serotonin receptor is expressed predominantly
by astrocytes in which it inhibits cAMP accumulation: a
mechanism for neuronal suppression of reactive astrocytes,”
GLIA, vol. 17, no. 4, pp. 317–326, 1996.
[75] J. L. Eriksen, R. Gillespie, and M. J. Druse, “Eﬀects of ethanol
and 5-HT1A agonists on astroglial S100B,” Developmental
Brain Research, vol. 139, no. 2, pp. 97–105, 2002.
[76] J. T. Porter and K. D. McCarthy, “Astrocytic neurotransmitter
receptors in situ and in vivo,” Progress in Neurobiology, vol. 51,
no. 4, pp. 439–455, 1997.
[77] A. Kleindienst, M. J. McGinn, H. B. Harvey, R. J. Colello, R.
J. Hamm, and M. R. Bullock, “Enhanced hippocampal neuro-
genesis by intraventricular S100B infusion is associated with
improved cognitive recovery after traumatic brain injury,”
Journal of Neurotrauma, vol. 22, no. 6, pp. 645–655, 2005.
[78] L. Santarelli, M. Saxe, C. Gross, et al., “Requirement of
hippocampalneurogenesisforthebehavioraleﬀectsofantide-
pressants,” Science, vol. 301, no. 5634, pp. 805–809, 2003.
[79] V. Arolt, M. Peters, A. Erfurth, et al., “S100B and response
to treatment in major depression: a pilot study,” European
Neuropsychopharmacology, vol. 13, no. 4, pp. 235–239, 2003.
[ 8 0 ] B .A rt s ,M .P e t e r s ,R .P o n d s ,A .H o n i g ,P .M e n h e e r e ,a n dJ .v a n
Os, “S100 and impact of ECT on depression and cognition,”
Journal of ECT, vol. 22, no. 3, pp. 206–212, 2006.